IDweek2023 | A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment

IDweek2023 | A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment

IDweek2023 A Comprehensive Analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) versus Dolutegravir/Lamivudine (DTG/3TC) in HIV Treatment In the relentless battle against HIV, the advent of antiretroviral therapy (ART) has marked a significant turning point. The development and introduction of drug regimens have revolutionized HIV treatment, transforming HIV from a fatal illness into a manageable chronic condition. However, the dynamic nature of the virus and its ability to develop resistance to drugs necessitates continuous research into new treatment strategies.
IDweek2023 | Exploring the Consequences of Low-Level Viremia Among Women with HIV

IDweek2023 | Exploring the Consequences of Low-Level Viremia Among Women with HIV

IDweek2023 Exploring the Consequences of Low-Level Viremia Among Women with HIV Understanding the dynamics of HIV infection is critical for managing and controlling the disease. A vital aspect of this understanding is the awareness of Low-Level Viremia (LLV), a condition experienced by about a third of people living with HIV. Despite its prevalence, there is a significant gap in clinical guidance on how to counsel and manage individuals with LLV.
IDweek2023 | Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy’s Role

IDweek2023 | Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy’s Role

IDweek2023 Hepatitis B Reactivation in HIV Patients: A Comprehensive Study of Antiretroviral Therapy's Role Hepatitis B, a viral infection that primarily affects the liver, can lead to serious complications, such as cirrhosis and hepatocellular carcinoma. In individuals living with HIV, the situation is further complicated since they face the risk of Hepatitis B reactivation - a condition that can occur when switching to antiretroviral therapy (ART) lacking Hepatitis B activity. This comprehensive article explores this complex medical phenomenon, providing a detailed understanding of its causative factors, implications, and potential strategies for patient management.